PO-REN HSUEH2020-12-182020-12-1820110929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/528558[SDGs]SDG3antibiotic agent; carbapenem; counterfeit drug; generic drug; pyrrole; quinoline derived antiinfective agent; Acinetobacter baumannii; antibiotic resistance; bacterial infection; Candida glabrata; Escherichia coli; health care policy; human; Klebsiella pneumoniae; Mycobacterium tuberculosis; mycosis; Neisseria gonorrhoeae; nonhuman; note; prescription; Pseudomonas aeruginosa; Streptococcus pneumoniae; world health organizationnote10.1016/S0929-6646(11)60032-62-s2.0-79957616942